Oncopeptides AB Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.11.20	Program for Oncopeptides virtual Capital Markets Day on November 30 is published (PR Newswire)
24.11.20	Program for Oncopeptides virtual Capital Markets Day on November 30 is published (PR Newswire)
19.11.20	Oncopeptides: INTERIM REPORT Q3 2020 (PR Newswire)
19.11.20	Oncopeptides: INTERIM REPORT Q3 2020 (PR Newswire)
05.11.20	Oncopeptides hosts a virtual capital markets day on November 30 (PR Newswire)
05.11.20	Oncopeptides hosts a virtual capital markets day on November 30 (PR Newswire)
04.11.20	Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation at the Annual American Society of Hematology Meeting (PR Newswire)
04.11.20	Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation at the Annual American Society of Hematology Meeting (PR Newswire)
03.11.20	Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
03.11.20	Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
21.10.20	Nomination committee in Oncopeptides established (PR Newswire)
21.10.20	Nomination committee in Oncopeptides established (PR Newswire)
19.10.20	Oncopeptides has submitted an Investigational New Drug application to FDA for the second drug candidate from the PDC platform (PR Newswire)
19.10.20	Oncopeptides has submitted an Investigational New Drug application to FDA for the second drug candidate from the PDC platform (PR Newswire)
14.10.20	Oncopeptides signs € 40 million loan agreement with the EIB (PR Newswire)
14.10.20	Oncopeptides signs € 40 million loan agreement with the EIB (PR Newswire)
12.10.20	With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA (PR Newswire)
12.10.20	With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA (PR Newswire)
01.10.20	Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma (PR Newswire)
01.10.20	Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma (PR Newswire)
08.09.20	Oncopeptides further aligns the US and global organizational structure and appoints Mohamed Ladha as General Manager of the US Business Unit (PR Newswire)
04.09.20	Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included (PR Newswire)
04.09.20	Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included (PR Newswire)
29.08.20	FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma (PR Newswire)
29.08.20	FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma (PR Newswire)
26.08.20	Oncopeptides AB: Interim Report Q2 2020 (PR Newswire)
26.08.20	Oncopeptides AB: Interim Report Q2 2020 (PR Newswire)
07.08.20	Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study (PR Newswire)
07.08.20	Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study (PR Newswire)
04.08.20	Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma (PR Newswire)
04.08.20	Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma (PR Newswire)
31.07.20	Number of shares and votes in Oncopeptides (PR Newswire)
31.07.20	Number of shares and votes in Oncopeptides (PR Newswire)
30.06.20	Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO (PR Newswire)
30.06.20	Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO (PR Newswire)
30.06.20	Number of Shares and Votes in Oncopeptides (PR Newswire)
30.06.20	Number of Shares and Votes in Oncopeptides (PR Newswire)
30.06.20	Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen in Triple-class Refractory Multiple Myeloma Patients (PR Newswire)
30.06.20	Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen in Triple-class Refractory Multiple Myeloma Patients (PR Newswire)
29.06.20	Oncopeptides Strengthens the Pre-clinical Development and Takes over Kancera's Solna-based Laboratory for Drug Development as of July 1 (PR Newswire)
29.06.20	Oncopeptides Strengthens the Pre-clinical Development and Takes over Kancera's Solna-based Laboratory for Drug Development as of July 1 (PR Newswire)
15.06.20	Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients (PR Newswire)
15.06.20	Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients (PR Newswire)
11.06.20	Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma (PR Newswire)
11.06.20	Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma (PR Newswire)
01.06.20	New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021 (PR Newswire)
01.06.20	New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021 (PR Newswire)
29.05.20	Number of shares and votes in Oncopeptides (PR Newswire)
29.05.20	Number of shares and votes in Oncopeptides (PR Newswire)
28.05.20	Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Oncopeptides AB Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten